Chief Executive Officer · SAB Biotherapeutics, Inc. (SABS)

Samuel Reich

A named executive officer of SAB Biotherapeutics in every fiscal year CompBrief holds from FY2021 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$9,434,622

Salary $525,000

FY2024: $2,582,790

1st of 5 named executive officers at SAB Biotherapeutics by FY2025 total.

5 named officers on file for SAB Biotherapeutics, FY2025

Samuel Reich’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SAB Biotherapeutics’s whole pay program stands against its peers

  • SAB Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SABS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Free

Get Samuel Reich’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Samuel Reich compensation by year

SAB Biotherapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as SAB Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023FY2024FY2025
Salary$52,731$350,000$350,000$518,300$525,000
Bonus$0$0$0——
Stock awards$0$0$0——
Option awards$2,741,235$304,600$202,598$1,800,690$8,588,160
Non-equity incentive$0$14,000$0$250,000$315,000
Pension and deferred compensation$0$0$0——
All other$1,660$12,200$13,200$13,800$6,462
Total$2,795,626$680,800$565,798$2,582,790$9,434,622

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SAB Biotherapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-197607, and prior-year filings. Open the filing on EDGAR.

How this page was built: the SAB Biotherapeutics, Inc. filed document, accession 0001193125-26-197607. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$2.8M
$681K
$566K
$2.6M
$9.4M
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option16,407—$5.35
Option9,844—$7.11
Option235,084—$5.17
Option23,057—$2.90
Option4,800,000—$2.17

Per the Outstanding Equity Awards at Fiscal Year-End table in SAB Biotherapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

SAB Biotherapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Samuel Reich · this pageChief Executive Officer$9,434,622
Eddie SullivanPresident$6,114,100
Alexandra KropotovaEVP, Chief Medical Officer$5,126,279
Lucy ToEVP, Chief Financial Officer$2,831,074
Christoph BauschEVP, Chief Operating Officer$1,682,520

Board service

SAB Biotherapeutics board · FY2021–FY2025
Director compensation in US dollars, as SAB Biotherapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025—————
FY2023$0$0$202,598—$202,598
FY2021$0$0$2,741,235—$2,741,235

Each year as the company reported it in SAB Biotherapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: SAB Biotherapeutics pays directors a $40,000 cash retainer and $150,000 in Options. As stated in SAB Biotherapeutics's FY2025 proxy.

The full SAB Biotherapeutics compensation record

free company brief

This page is one person within SAB Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SAB Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Samuel Reich's compensation dossier · One-time report. No refunds.